These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

313 related items for PubMed ID: 15554761

  • 21. [Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance].
    Besnard I, Auclair V, Callery G, Gabriel-Bordenave C, Roberge C.
    Encephale; 2014 Feb; 40(1):86-94. PubMed ID: 23928066
    [Abstract] [Full Text] [Related]

  • 22. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism.
    Misra M, Papakostas GI, Klibanski A.
    J Clin Psychiatry; 2004 Dec; 65(12):1607-18; quiz 1590, 1760-1. PubMed ID: 15641865
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. [Prolactin secretion disturbances in schizophrenic patients treated with 2nd generation antipsychotics--risperidone and olanzapine].
    Wyszogrodzka-Kucharska A, Kunert-Radek J, Rabe-Jabłońska J.
    Psychiatr Pol; 2005 Dec; 39(6):1143-55. PubMed ID: 16526181
    [Abstract] [Full Text] [Related]

  • 25. Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients.
    Melkersson K.
    J Clin Psychiatry; 2005 Jun; 66(6):761-7. PubMed ID: 15960571
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine.
    Kinon BJ, Ahl J, Liu-Seifert H, Maguire GA.
    Psychoneuroendocrinology; 2006 Jun; 31(5):577-88. PubMed ID: 16488084
    [Abstract] [Full Text] [Related]

  • 29. Threshold of Dopamine D2/3 Receptor Occupancy for Hyperprolactinemia in Older Patients With Schizophrenia.
    Iwata Y, Nakajima S, Caravaggio F, Suzuki T, Uchida H, Plitman E, Chung JK, Mar W, Gerretsen P, Pollock BG, Mulsant BH, Rajji TK, Mamo DC, Graff-Guerrero A.
    J Clin Psychiatry; 2016 Dec; 77(12):e1557-e1563. PubMed ID: 28086010
    [Abstract] [Full Text] [Related]

  • 30. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management.
    Haddad PM, Wieck A.
    Drugs; 2004 Dec; 64(20):2291-314. PubMed ID: 15456328
    [Abstract] [Full Text] [Related]

  • 31. Hormonal side effects in women: typical versus atypical antipsychotic treatment.
    Dickson RA, Seeman MV, Corenblum B.
    J Clin Psychiatry; 2000 Dec; 61 Suppl 3():10-5. PubMed ID: 10724128
    [Abstract] [Full Text] [Related]

  • 32. The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis.
    Smith S, Wheeler MJ, Murray R, O'Keane V.
    J Clin Psychopharmacol; 2002 Apr; 22(2):109-14. PubMed ID: 11910254
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Positron emission tomography measurement of dopamine D₂ receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia.
    Arakawa R, Okumura M, Ito H, Takano A, Takahashi H, Takano H, Maeda J, Okubo Y, Suhara T.
    J Clin Psychiatry; 2010 Sep; 71(9):1131-7. PubMed ID: 20361897
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.